NCT03840408

Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer

Prospective Clinical Study of Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 1,753 (estimated)
• Sponsor: Shanghai 10th People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Lung cancer is the leading cause of cancer related mortality. Among them, non small cell lung cancer accounts for 85%. Only part of patients could be treated with radical surgery. Mitochondria-targeted system therapy combined with radiofrequency ablation could be an alternative treatment. Small sample clinical cases verified that this therapy could be an efficacy and safe treatment in a short period. The primary aim of this trial is to determine if the efficacy of mitochondria-targeted system therapy combined with radiofrequency ablation is comparable to that of standard surgical interventions for patients with non-small cell lung cancer.

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
OTHER	Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation	Patients will be treated with mitochondria-targeted system therapy and radiofrequency ablation in the primary tumor sites
PROCEDURE	Surgery	Patients will be treated with surgery

Timeline

• Start date: 2019-01-31
• Primary completion: 2024-01-31
• Completion: 2024-01-31
• First posted: 2019-02-15
• Last updated: 2019-02-20

Locations

1 site across 1 country: China